English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/143357
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 3 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar bibText (RIS)Exportar csv (RIS)
Título

Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery

Autor Marques, Joana; Valle-Delgado, Juan J.; Urbán, Patricia; Baró, Elisabet; Prohens, Rafel; Mayor, Alfredo; Cisteró, Pau; Delves, Michael; Sinden, Robert E.; Grandfils, Christian; Paz, José L. de; García-Salcedo, José A.; Fernández-Busquets, Xavier
Palabras clave Glycosaminoglycans
Malaria
Nanomedicine
Plasmodium
Targeted drug delivery
Fecha de publicación 2017
EditorElsevier
Citación Nanomedicine - Nanotechnology Biology and Medicine, 13:515-525 (2017)
ResumenThe adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems
Versión del editorhttp://dx.doi.org/10.1016/j.nano.2016.09.010
URI http://hdl.handle.net/10261/143357
DOI10.1016/j.nano.2016.09.010
Aparece en las colecciones: (IIQ) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Nanomedicine.pdf1,44 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.